Current stage -Stage IV Posts on Medivizor

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Jul 7, 2024 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide in combination with ADT improved the overall survival over the long term with...

Does statin use improve survival outcomes in men with advanced prostate cancer undergoing androgen deprivation therapy?

Posted by Medivizor on Sep 17, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the association between statin (cholesterol-lowering drugs) use and survival outcomes in men with advanced prostate cancer (PC) undergoing androgen deprivation therapy (ADT). The data showed that statin use improved the survival outcomes in these patients. Some background Metastatic prostate cancer (PC) is a form of...

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Posted by Medivizor on Aug 27, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of panitumumab (Vectibix) rechallenge when added to maintenance therapy with FOLFIRI {fluorouracil (FU; Adrucil), folinic acid (FA; Leucovorin), irinotecan (Camptosar)} in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with...

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Posted by Medivizor on Jun 11, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the...

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 11, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Posted by Medivizor on May 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple-negative breast cancer (TNBC). This study concluded that the combination of taxanes and chemotherapy is effective with manageable side effects in these patients. Some background TNBC is a subtype of BC that tests...

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Apr 30, 2023 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety of radium-223 dichloride (Xofigo) treatment in real-world patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that radium-223 dichloride treatment was well tolerated and reduced pain in real-world patients with mCRPC spread to the bone. Some...

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Posted by Medivizor on Apr 15, 2023 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of relatlimab (Opdualag) and nivolumab (Opdivo) combination therapy before surgery in patients with stages III and IV resectable melanoma. The study concluded that the relatlimab and nivolumab combination was safe and effective in these patients. Some background...

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Posted by Medivizor on Mar 26, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated which sequence of treatment should be given first – immunotherapy or targeted therapy – for the most clinical benefit in patients with BRAF-mutated metastatic melanoma. The data showed that immunotherapy followed by targeted therapy significantly improved survival outcomes in these patients. Some background...

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Posted by Medivizor on Mar 5, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients. Some background Colorectal cancer (CRC) is one of the most common...

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Mar 5, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Posted by Medivizor on Mar 5, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) either alone or in combination for the treatment of patients with advanced melanoma. The data showed that nivolumab (Opdivo) and ipilimumab (Yervoy) combination therapy was more effective than nivolumab or ipilimumab alone for the treatment of...

Current stage -Stage IV Posts on Medivizor

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Does statin use improve survival outcomes in men with advanced prostate cancer undergoing androgen deprivation therapy?

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Evaluating the safety and effectiveness of nivolumab and relatlimab before surgery in patients with resectable melanoma

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Categories

Recent Posts

Archives

Current stage -Stage IV Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email